Krishna Ella

In 2003, the RA Mashelkar Committee said that a strong, well-equipped, empowered, independent and professionally-managed CDSCO, which could be given the status of Central Drug Administration, reporting directly to the Ministry of Health would be the most appropriate solution.

3 lakh doses of intranasal Covid vaccine sent to hospitals: Bharat Biotech's Krishna Ella

He was speaking on the sidelines of an event here at which a bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.

Merge state, central drug regulators for better standards: Bharat Biotech chairman

In the past few months, there have been repeated instances of foreign drug regulators raising the red flag against medicines manufactured by Indian pharmaceutical firms

Indian Pharmaceutical Congress: Bharat Biotech founder bats for incentives, tax breaks for patented products, innovation

"Research linked incentive for Indian companies is very important. I would request the ministry to give tax breaks to any product that is created from patent filed in India. It will inspire entrepreneurs to go for innovation," he said.

Bharat Biotech partners with CEPI to develop ‘variant-proof’ COVID-19 vaccine

The international multidisciplinary consortium comprising Bharat Biotech International, the University of Sydney and ExcellGene SA, Switzerland will receive funding of $19.3 million to support the development of a ‘variant-proof’ coronavirus vaccine candidate.

Bharat Biotech Chairman Krishna Ella donates Rs 2 crore to Tirumala Tirupati Devasthanams run trust

The official further said the devotees requested the TTD to utilise the donation amount for the temple-run pilgrim free meal trust called Sri Venkateswara Annaprasadam Trust.

Ideal time for booster dose for COVID vaccine is 6 months after 2nd dose: Bharat Biotech MD Krishna Ella

The ideal time for a booster dose is six months after the second dose," Ella stated. ”The ideal time for a booster dose is six months after the second dose,” Ella stated. Bharat Biotech is also looking at nasal vaccine as a booster dose as its scaling up capacity is very easy when compared with Covaxin, he added.

Paediatric Covaxin | Bharat Biotech completes phase 2/3 trials

Speaking to reporters, Krishna Ella said Covaxin production would touch 55 million doses in October as against 35 million in September.

Pfizer, Moderna vaccines wouldn't have got nod had they done phase 3 trials in 2nd wave: Krishna Ella

Hyderabad-based Bharat Biotech, the manufacturer of COVID-19 Covaxin, said the efficacy of its vaccine would have been 85 percent against the original strain of the virus -- the one that was first detected in China.

India has done better than any country across world in vaccination: Bharat Biotech CMD

About the contribution and efforts of Bharat Biotech in regards to vaccination efforts, Krishna Ella said that apart from Covaxin, the company has also developed a intranasal vaccine for COVID-19.

Bharat Biotech ties up with CSIR-IICT to locally make vaccine raw materials

Bharat Biotech signed a master collaborative agreement with Biovet and Sapigen Biologix. Under the agreement all the firms would provide necessary financial support to CSIR-IICT for developing key raw materials.

Covaxin vs Covishield: Bharat Biotech, Serum Institute CEOs take a jab at each other, here is what they said

Bharat Biotech Chairman Krishna Ella apparently hit back at Serum Institute of India chief Adar Poonawalla’s jibe calling vaccines other than those by AstraZeneca, Moderna and Pfizer as 'like water'.

Unfair to accuse us of inexperience, Covaxin Phase-3 efficacy data by March: Bharat Biotech Chairman Krishna Ella

The Drugs Controller General of India on January 3 approved Bharat Biotech's COVID-19 vaccine 'Covaxin' for conducting trials on children above the age of 12 years.

People who are infected should also take vaccine: Bharat Biotech Chairman Krishna Ella

Krishna Ella was speaking in a virtual session on 'Sero surveillance significance in immunogenicity and safety in pre and post vaccination era' organised by industry body CII.

China, Korea overtaking India in vaccine exports: Experts

Vaccine exports from the country plunged by eight per cent during 2016-17 and nearly four per cent in the previous fiscal year. India exported vaccines worth $653.40 million in 2017-18 while it was $679.28 million in 2016-17.